The VA-MAPP is here – Prostate Cancer Foundation
Prostate Cancer Foundation shared on X:
“The VA-MAPP (Multi-OMICS Analysis Platform for Prostate Cancer) is here! This powerful platform can be used for research on incidence, disparities, novel detection methods, treatment patterns, biomarker development, and more.”
The session focused on the critical importance of diversity and equity in clinical trials, emphasizing efforts to ensure participant demographics reflect the populations served by healthcare institutions. It was highlighted that African American patients are enrolling in clinical trials at rates matching their representation within the center, demonstrating a strong commitment to inclusivity and addressing historical underrepresentation. This progress is vital for generating generalizable data, reducing healthcare disparities, and fostering trust in underserved communities.
Gabriel Haas of Ellos Pharma Global Development expressed gratitude for the transparency and commended the session for addressing these critical issues. He highlighted the importance of collective attention and action in advancing diversity, equity, and inclusion in healthcare research. The discussion underscored the need for sustained efforts to ensure clinical trials are accessible and representative of all populations.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023